Published in Proteomics Weekly, October 5th, 2009
Principal investigator of the study, Professor Jose Baselga told Europe's largest cancer congress, ECCO 15 - ESMO 34 , in Berlin today (Wednesday 23 September): "This is the first, large, randomised study that demonstrates significant clinical activity of sorafenib in breast cancer when given in combination with chemotherapy. Our results showed that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly